Corneal infections are important causes of blindness and occur in epidemic proportions in low- and mid-income countries. The etiology of the disease varies from region to region but bacteria account for a large majority of these cases. Pseudomonas aeruginosa is an important pathogen that causes a rapidly progressive disease. In many cases, patients are left with stromal scarring, irregular astigmatism, require transplant or in the worst case scenario, lose an eye1,2.
Bacterial keratitis caused by P. aeruginosa is a difficult eye infection to treat particularly due to the increasing emergence of antimicrobial resistant strains of P. aeruginosa. Within the last decade, it has become apparent that testing and developing new treatments for corneal infections, in general, and those caused by Pseudomonas sp., in particular, are essential to combat the current trend in antibiotic resistance3.
For testing the efficacy of new treatments for corneal infections, conventional in vitro microbiological methods are a poor surrogate due to the difference in bacterial physiology during laboratory culture and during infections in vivo as well as due to the lack of the host interface4,5. In vivo animal models, however, are expensive, time-consuming, can only deliver a small number of replicates and raise concerns about animal welfare.
In this article, we demonstrate a simple and reproducible organotypic ex vivo porcine model of keratitis that can be used to test various treatments for acute and chronic infections. We have used P. aeruginosa for this experiment but the model also works well with other bacteria, and organisms such as fungi and yeast which cause keratitis.